CAPABILITIES

Scientific capabilities organised around the development question.

Synprecia helps clients identify, access and coordinate the capabilities required to generate useful preclinical evidence. The exact combination is defined for each program.

Discuss Your Program
01

Discovery and translational pharmacology

  • Target validation strategy
  • Mechanism-of-action studies
  • Biochemical and cell-based assay planning
  • Disease-relevant model selection
  • Translational hypothesis development
  • Proof-of-concept planning
  • Pharmacodynamic endpoint planning
02

In vivo efficacy

  • Model-landscape assessment
  • Pilot-study planning
  • Dose and schedule considerations
  • Endpoint selection
  • Randomisation and control strategy
  • Translational relevance review
  • Follow-up study planning
03

ADME, DMPK and pharmacokinetics

  • In vitro ADME strategy
  • Metabolic stability
  • Permeability and transporters
  • Protein binding
  • Pharmacokinetic study design
  • Exposure assessment
  • PK/PD integration
  • Bioanalytical coordination
04

Bioanalysis and biomarkers

  • Bioanalytical-method requirements
  • Fit-for-purpose validation strategy
  • Pharmacodynamic biomarker planning
  • Translational biomarker selection
  • Sample logistics
  • Cross-study comparability
05

Safety and toxicology planning

  • Early safety-question identification
  • Exploratory toxicology planning
  • Dose-range-finding considerations
  • Safety pharmacology planning
  • Species rationale
  • Pathology coordination
  • Toxicology data integration
06

Formulation and delivery interface

  • Preclinical formulation requirements
  • Route-of-administration considerations
  • Solubility and stability questions
  • Vehicle selection
  • Cross-provider consistency
  • Material logistics
07

Pathology and tissue-based analysis

  • Tissue collection planning
  • Histology workflow coordination
  • Pathology-review strategy
  • Immunohistochemistry planning
  • Digital pathology
  • Integrated interpretation
08

Integrated scientific reporting

  • Cross-study evidence integration
  • Data-summary tables
  • Decision-focused reporting
  • Development-gap summary
  • Risk communication
  • Recommendations for next studies
Safety and quality note. Precise regulatory and quality requirements must be confirmed for the relevant product, jurisdiction and pathway. Synprecia does not represent unverified regulatory status or laboratory accreditation.

MODALITIES

Programs may involve different therapeutic modalities.

Capability and modality support are confirmed individually after program review.

  • Small molecules
  • Biologics
  • Antibodies
  • Peptides
  • Oligonucleotides
  • Advanced therapeutic approaches
  • Drug-device combinations
  • Platform technologies

START A CONVERSATION

A capability is valuable only when it answers the right question.

Discuss the evidence your program needs to generate.

Discuss Your Scientific Requirementsbd@synprecia.com